AstraZeneca announces AEGEAN phase III trial of Imfinzi shows significantly improved EFS for patients with resectable early-stage NSCLC

Positive high-level results from a planned interim analysis of the AEGEAN phase III, placebo- controlled trial showed that treatment with AstraZeneca